[go: up one dir, main page]

EP2814504A4 - PROTEASE INHIBITORY COMPOSITIONS, COMPOSITIONS THEREWITH AND METHOD FOR THE PRODUCTION AND USE THEREOF - Google Patents

PROTEASE INHIBITORY COMPOSITIONS, COMPOSITIONS THEREWITH AND METHOD FOR THE PRODUCTION AND USE THEREOF

Info

Publication number
EP2814504A4
EP2814504A4 EP13744410.5A EP13744410A EP2814504A4 EP 2814504 A4 EP2814504 A4 EP 2814504A4 EP 13744410 A EP13744410 A EP 13744410A EP 2814504 A4 EP2814504 A4 EP 2814504A4
Authority
EP
European Patent Office
Prior art keywords
compositions
production
therewith
protease inhibitory
inhibitory compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP13744410.5A
Other languages
German (de)
French (fr)
Other versions
EP2814504B1 (en
EP2814504A1 (en
Inventor
Avraham Hershko
Miriam Kidron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oramed Ltd
Original Assignee
Oramed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oramed Ltd filed Critical Oramed Ltd
Priority to DK22162188.1T priority Critical patent/DK4082530T5/en
Priority to EP22162188.1A priority patent/EP4082530B1/en
Publication of EP2814504A1 publication Critical patent/EP2814504A1/en
Publication of EP2814504A4 publication Critical patent/EP2814504A4/en
Application granted granted Critical
Publication of EP2814504B1 publication Critical patent/EP2814504B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
EP13744410.5A 2012-02-01 2013-01-31 Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same Active EP2814504B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DK22162188.1T DK4082530T5 (en) 2012-02-01 2013-01-31 COMPOSITIONS CONTAINING PROTEASE INHIBITORS, COMPOSITIONS INCLUDING THE SAME AND METHODS OF PREPARING AND USING THE SAME
EP22162188.1A EP4082530B1 (en) 2012-02-01 2013-01-31 Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261632868P 2012-02-01 2012-02-01
US201261634753P 2012-03-06 2012-03-06
PCT/IL2013/050091 WO2013114369A1 (en) 2012-02-01 2013-01-31 Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP22162188.1A Division EP4082530B1 (en) 2012-02-01 2013-01-31 Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same

Publications (3)

Publication Number Publication Date
EP2814504A1 EP2814504A1 (en) 2014-12-24
EP2814504A4 true EP2814504A4 (en) 2015-10-14
EP2814504B1 EP2814504B1 (en) 2022-03-16

Family

ID=48904507

Family Applications (2)

Application Number Title Priority Date Filing Date
EP22162188.1A Active EP4082530B1 (en) 2012-02-01 2013-01-31 Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same
EP13744410.5A Active EP2814504B1 (en) 2012-02-01 2013-01-31 Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP22162188.1A Active EP4082530B1 (en) 2012-02-01 2013-01-31 Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same

Country Status (9)

Country Link
US (4) US10342764B2 (en)
EP (2) EP4082530B1 (en)
JP (3) JP6567827B2 (en)
CN (3) CN104244969A (en)
DK (2) DK4082530T5 (en)
ES (1) ES2912138T3 (en)
HK (1) HK1200727A1 (en)
HU (1) HUE066433T2 (en)
WO (1) WO2013114369A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180228621A1 (en) 2004-08-09 2018-08-16 Mark A. Reiley Apparatus, systems, and methods for the fixation or fusion of bone
CA2621577C (en) * 2005-09-06 2013-12-24 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
JP5395160B2 (en) 2008-03-26 2014-01-22 オラムド エルティーディー． Method and composition for oral administration of protein
BRPI0908292B1 (en) 2008-05-05 2022-09-20 Oramed Ltd METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF EXENATIDE
EP2800579B1 (en) 2012-01-03 2017-08-30 Oramed Ltd. Capsules containing oil-based liquid compositions of combined therapeutic agents for treating diabetes
DK4082530T5 (en) 2012-02-01 2024-07-22 Oramed Ltd COMPOSITIONS CONTAINING PROTEASE INHIBITORS, COMPOSITIONS INCLUDING THE SAME AND METHODS OF PREPARING AND USING THE SAME
US10363140B2 (en) 2012-03-09 2019-07-30 Si-Bone Inc. Systems, device, and methods for joint fusion
IN2014DN06946A (en) 2012-03-09 2015-04-10 Si Bone Inc
EP3479778B1 (en) 2012-05-04 2020-09-16 SI-Bone, Inc. Fenestrated implant
EP2941267B1 (en) 2013-01-03 2022-11-16 Oramed Ltd. Compositions for use in treating nafld
US9936983B2 (en) 2013-03-15 2018-04-10 Si-Bone Inc. Implants for spinal fixation or fusion
US11147688B2 (en) 2013-10-15 2021-10-19 Si-Bone Inc. Implant placement
WO2016044731A1 (en) 2014-09-18 2016-03-24 Si-Bone Inc. Implants for bone fixation or fusion
EP3782586A1 (en) 2014-09-18 2021-02-24 SI-Bone, Inc. Matrix implant
CN105343184A (en) * 2015-12-01 2016-02-24 无限极（中国）有限公司 Composition and application thereof
WO2017161184A1 (en) * 2016-03-16 2017-09-21 Amidebio, Llc Methods for producing peptides and uses thereof
EP3687422A4 (en) 2017-09-26 2021-09-22 SI-Bone, Inc. Systems and methods for decorticating the sacroiliac joint
MX2020013296A (en) * 2018-06-11 2021-05-27 Oramed Ltd Recombinant protease inhibitor-containing compositions, methods for producing same and uses thereof.
US11369419B2 (en) 2019-02-14 2022-06-28 Si-Bone Inc. Implants for spinal fixation and or fusion
AU2020223180A1 (en) 2019-02-14 2021-07-22 Si-Bone Inc. Implants for spinal fixation and or fusion
JP2023505055A (en) 2019-11-27 2023-02-08 エスアイ－ボーン・インコーポレイテッド Bone Stabilizing Implant and Method of Placement Across the Sacroiliac Joint
AU2020402850A1 (en) 2019-12-09 2022-06-09 Si-Bone Inc. Sacro-iliac joint stabilizing implants and methods of implantation
WO2022125619A1 (en) 2020-12-09 2022-06-16 Si-Bone Inc. Sacro-iliac joint stabilizing implants and methods of implantation
WO2023017537A1 (en) * 2021-08-12 2023-02-16 Celagenex Research (India) Pvt. Ltd. Oral algal oil based gastro-intestinal tract permeable peptide composition
CN117186237A (en) * 2022-05-29 2023-12-08 中国医学科学院药物研究所 Insulin hybrid peptide containing chymotrypsin inhibitory peptide and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013102899A1 (en) * 2012-01-03 2013-07-11 Oramed Ltd. Methods and compositions for treating diabetes

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
JPS6350793A (en) 1986-08-20 1988-03-03 株式会社東芝 Decay heat removing system of fast breeder reactor
US5034415A (en) 1987-08-07 1991-07-23 Century Laboratories, Inc. Treatment of diabetes mellitus
DE68909135T2 (en) 1988-07-21 1994-04-07 Hoffmann La Roche Insulin preparation.
JPH02250823A (en) 1989-03-24 1990-10-08 Tsumura & Co Microcapsule agent and production thereof
GB9007052D0 (en) 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
JPH06145198A (en) * 1992-03-30 1994-05-24 Shokuhin Sangyo High Separeeshiyon Syst Gijutsu Kenkyu Kumiai Production of soybean trypsin inhibitor
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
IL114673A (en) 1995-07-19 2000-12-06 Hadasit Med Res Service Pharmaceutical compositions containing protein for oral administration
JPH09208485A (en) 1996-01-31 1997-08-12 Teijin Ltd Scarcely water-soluble composition of peptide/protein medicine
ATE493998T1 (en) 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc PHARMACEUTICAL COMPOSITION CONTAINING AN EXENDIN-4 PEPTIDE
JPH10330287A (en) 1997-03-31 1998-12-15 Nippon Suisan Kaisha Ltd Digestive absorption promoter comprising polyvalent unsaturated fatty acid, and preparation containing the same
JP2000128805A (en) 1998-10-27 2000-05-09 Nippon Suisan Kaisha Ltd Trans-mucosal absorption promoter comprising polyvalent unsaturated fatty acid and polymer gel and pharmaceutical preparation containing the same
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
JP2001240558A (en) 2000-02-29 2001-09-04 Nippon Suisan Kaisha Ltd Solid preparation containing polyvalent-unsaturated fatty acid as transmucosal absorption promoter
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
KR20010069322A (en) 2001-03-08 2001-07-25 서종수 An electric auction method using PDA or IMT2000
KR20010069433A (en) 2001-03-22 2001-07-25 김윤완 Hernacium Erinaceum use health assistance food
CN1160122C (en) * 2001-04-20 2004-08-04 清华大学 A kind of method for preparing oral insulin oil phase preparation
CN1741805A (en) 2001-07-18 2006-03-01 索莱有限责任公司 High protein Bowman-Birk inhibitor concentrate and method for its production
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
JP4165329B2 (en) * 2002-07-31 2008-10-15 不二製油株式会社 Production method of soybean whey fraction
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20050143303A1 (en) 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
AU2005329255B2 (en) 2004-04-15 2010-09-30 Chiasma, Inc. Compositions capable of facilitating penetration across a biological barrier
WO2006014673A2 (en) 2004-07-19 2006-02-09 Nobex Corporation Insulin-oligomer conjugates, formulations and uses thereof
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
WO2006025882A2 (en) 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
WO2006057551A1 (en) 2004-11-26 2006-06-01 N.V. Nutricia Infant nutrition with protease inhibitor
CA2621577C (en) 2005-09-06 2013-12-24 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
US20070086972A1 (en) 2005-09-12 2007-04-19 Jacob Birnbaum Hair growth compositions and methods for treating hair loss or related conditions
US20070077283A1 (en) 2005-09-30 2007-04-05 Nastech Pharmaceutical Company Inc. Method of enhancing transmucosal delivery of therapeutic compounds
CN101095942B (en) 2006-06-30 2011-11-16 北京民海生物科技有限公司 Formulation of the Exendin injection medicine containing stabilizing agent
JP5395160B2 (en) * 2008-03-26 2014-01-22 オラムド エルティーディー． Method and composition for oral administration of protein
BRPI0908292B1 (en) 2008-05-05 2022-09-20 Oramed Ltd METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF EXENATIDE
CA2729296A1 (en) 2008-06-17 2010-01-28 Richard D. Dimarchi Gip-based mixed agonists for treatment of metabolic disorders and obesity
US9186412B2 (en) 2008-08-18 2015-11-17 Entera Bio Ltd. Methods and compositions for oral administration of insulin
EP2785730A1 (en) * 2009-12-30 2014-10-08 Solae, LLC Method for recovering kunitz-trypsin inhibitor proteins from a soy processing stream
DK4082530T5 (en) 2012-02-01 2024-07-22 Oramed Ltd COMPOSITIONS CONTAINING PROTEASE INHIBITORS, COMPOSITIONS INCLUDING THE SAME AND METHODS OF PREPARING AND USING THE SAME
EP2941267B1 (en) 2013-01-03 2022-11-16 Oramed Ltd. Compositions for use in treating nafld
MX2020013296A (en) 2018-06-11 2021-05-27 Oramed Ltd Recombinant protease inhibitor-containing compositions, methods for producing same and uses thereof.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013102899A1 (en) * 2012-01-03 2013-07-11 Oramed Ltd. Methods and compositions for treating diabetes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MORISHITA M ET AL: "Novel oral microspheres of insulin with protease inhibitor protecting from enzymatic degradation", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 78, no. 1-3, 1 January 1992 (1992-01-01), pages 1 - 7, XP025557871, ISSN: 0378-5173, [retrieved on 19920101], DOI: 10.1016/0378-5173(92)90348-6 *
NANA A. YEBOAH ET AL: "A Rapid Purification Method for Soybean Bowman-Birk Protease Inhibitor Using Hydrophobic Interaction Chromatography", PROTEIN EXPRESSION AND PURIFICATION, vol. 7, no. 3, 1 May 1996 (1996-05-01), pages 309 - 314, XP055071879, ISSN: 1046-5928, DOI: 10.1006/prep.1996.0044 *
See also references of WO2013114369A1 *

Also Published As

Publication number Publication date
DK2814504T3 (en) 2022-05-02
JP2015510506A (en) 2015-04-09
US20140377344A1 (en) 2014-12-25
US20210369626A1 (en) 2021-12-02
US20190321303A1 (en) 2019-10-24
EP2814504B1 (en) 2022-03-16
US10342764B2 (en) 2019-07-09
US10933022B2 (en) 2021-03-02
DK4082530T3 (en) 2024-05-06
US20240358647A1 (en) 2024-10-31
CN112755002A (en) 2021-05-07
JP2020117518A (en) 2020-08-06
ES2912138T3 (en) 2022-05-24
HUE066433T2 (en) 2024-08-28
CN113769074A (en) 2021-12-10
JP6567827B2 (en) 2019-08-28
EP2814504A1 (en) 2014-12-24
HK1200727A1 (en) 2015-08-14
CN104244969A (en) 2014-12-24
WO2013114369A1 (en) 2013-08-08
EP4082530A1 (en) 2022-11-02
EP4082530B1 (en) 2024-04-10
DK4082530T5 (en) 2024-07-22
JP7064226B2 (en) 2022-05-10
JP2018104443A (en) 2018-07-05

Similar Documents

Publication Publication Date Title
EP2814504A4 (en) PROTEASE INHIBITORY COMPOSITIONS, COMPOSITIONS THEREWITH AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP3389630A4 (en) NEOANTIGENT IDENTIFICATION, PRODUCTION AND USE
EP2804214A4 (en) SEMICONDUCTOR COMPONENT AND METHOD FOR THE PRODUCTION THEREOF
EP2819293A4 (en) GELACTUATOR AND METHOD FOR THE PRODUCTION THEREOF
EP2995589A4 (en) ANODEACTIVE MATERIAL AND METHOD FOR THE PRODUCTION THEREOF
BR112013033811A2 (en) composition, method of preparing the composition, and
EP2818585A4 (en) FILM-EDGING DEVICE AND FILM-FORMING METHOD FOR THE PRODUCTION OF METAL LAYERS
EP2760879C0 (en) PROTEIN ADHESIVES, THEIR PRODUCTION AND USE
EP2816006A4 (en) POROUS BODY AND METHOD FOR THE PRODUCTION THEREOF
EP2817439A4 (en) ALUMINUM ALLOY, ALUMINUM ALLOY RESIN COMPOSITE AND METHOD FOR THE PRODUCTION THEREOF
EP2785668A4 (en) LIQUIDIZED COMPOSITIONS, MANUFACTURING METHOD AND USES THEREOF
EP2832708A4 (en) METHOD FOR THE PRODUCTION OF MONOLITHIC, CARBONIC OR CERAMIC SYSTEMS
EP2822998A4 (en) Compatibilized composition, method for the formation thereof, and article comprising same
EP2805336A4 (en) SUPERCONDITIONING WIRE AND METHOD FOR THE PRODUCTION THEREOF
EP3129094C0 (en) BOUGIE AND METHOD FOR THE PRODUCTION THEREOF
EP3713900C0 (en) NPK-SI-HUMAT FERTILIZER, METHOD FOR THE PRODUCTION AND USE THEREOF
EP3358603A4 (en) SEMICONDUCTOR COMPONENT AND METHOD FOR THE PRODUCTION THEREOF
EP2681280A4 (en) BIOMATERIAL, METHOD FOR PRODUCING THE BIOMATERIAL AND USES THEREOF
DE112013006065A5 (en) Method for producing semiconductor laser elements and semiconductor laser element
EP3557669A4 (en) ELECTRODE, REDOX FLOW BATTERY AND METHOD FOR PRODUCING THE ELECTRODE
EP2809782A4 (en) IMPROVED METHOD FOR THE PRODUCTION OF MACROPERLES
EP3551619A4 (en) COMPOSITIONS WITH METHYLPHENIDATE PRODRUGS, METHOD FOR THE PRODUCTION AND USE THEREOF
EP2939997A4 (en) POLYETHERDIOL AND METHOD FOR THE PRODUCTION THEREOF
EP2972568C0 (en) METHOD FOR DESIGNING AND MANUFACTURING CUSTOMIZED GLASSES
RS58386B1 (en) ORMARIC, PROCEDURE FOR THE PRODUCTION OF THE ORMARIC

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140901

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HERSHKO, AVRAHAM

Inventor name: KIDRON, MIRIAM

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150914

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/66 20060101ALI20150908BHEP

Ipc: A61K 9/08 20060101AFI20150908BHEP

Ipc: A61K 38/26 20060101ALI20150908BHEP

Ipc: A61K 38/28 20060101ALI20150908BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180727

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602013081132

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0038550000

Ipc: A61K0038170000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 43/00 20060101ALI20210902BHEP

Ipc: A61P 3/08 20060101ALI20210902BHEP

Ipc: A61K 9/48 20060101ALI20210902BHEP

Ipc: A61K 9/19 20060101ALI20210902BHEP

Ipc: A61K 47/42 20170101ALI20210902BHEP

Ipc: A61K 38/56 20060101ALI20210902BHEP

Ipc: A61K 38/28 20060101ALI20210902BHEP

Ipc: A61K 38/26 20060101ALI20210902BHEP

Ipc: A61K 38/17 20060101AFI20210902BHEP

INTG Intention to grant announced

Effective date: 20210923

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013081132

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1475423

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220415

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20220427

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2912138

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20220524

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20220316

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220316

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220316

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220616

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220316

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220316

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220616

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1475423

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220316

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220316

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220617

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220316

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220316

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220316

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220316

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220316

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220718

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220316

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220316

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220316

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220316

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220716

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220316

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013081132

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20221219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220316

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230511

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230131

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240216

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240119

Year of fee payment: 12

Ref country code: CH

Payment date: 20240202

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240131

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220316

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220316

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20241120

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20241120

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20241120

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20241121

Year of fee payment: 13